Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease

Jennifer R. Mammen*, Rebecca M. Speck, Glenn T. Stebbins, Martijn L.T.M. Müller, Phillip T. Yang, Michelle Campbell, Josh Cosman, John E. Crawford, Tien Dam, Johan Hellsten, Stella Jensen-Roberts, Melissa Kostrzebski, Tanya Simuni, Kimberly Ward Barowicz, Jesse M. Cedarbaum, E. Ray Dorsey, Diane Stephenson, Jamie L. Adams

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background: Patient perspectives on meaningful symptoms and impacts in early Parkinson's disease (PD) are lacking and are urgently needed to clarify priority areas for monitoring, management, and new therapies. Objective: To examine experiences of people with early-stage PD, systematically describe meaningful symptoms and impacts, and determine which are most bothersome or important. Methods: Forty adults with early PD who participated in a study evaluating smartwatch and smartphone digital measures (WATCH-PD study) completed online interviews with symptom mapping to hierarchically delineate symptoms and impacts of disease from 'Most bothersome' to 'Not present,' and to identify which of these were viewed as most important and why. Individual symptom maps were coded for types, frequencies, and bothersomeness of symptoms and their impacts, with thematic analysis of narratives to explore perceptions. Results: The three most bothersome and important symptoms were tremor, fine motor difficulties, and slow movements. Symptoms had the greatest impact on sleep, job functioning, exercise, communication, relationships, and self-concept-commonly expressed as a sense of being limited by PD. Thematically, most bothersome symptoms were those that were personally limiting with broadest negative impact on well-being and activities. However, symptoms could be important to patients even when not present or limiting (e.g., speech, cognition). Conclusion: Meaningful symptoms of early PD can include symptoms that are present or anticipated future symptoms that are important to the individual.

Original languageEnglish (US)
Pages (from-to)619-632
Number of pages14
JournalJournal of Parkinson's disease
Volume13
Issue number4
DOIs
StatePublished - Jun 13 2023

Funding

This study was funded by the Critical Path for Parkinson’s (CPP) Consortium. The CPP 3DT initiative is funded by the CPP Consortium members including Biogen; GSK; Takeda; Lundbeck; UCB Pharma; Roche; AbbVie and Merck, Parkinson’s UK, and the Michael J Fox Foundation. Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

Keywords

  • Parkinson's disease
  • digital health technology
  • meaningfulness
  • qualitative

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease'. Together they form a unique fingerprint.

Cite this